Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589875 | 0.81 | KCNH2 (0.34) | EGFRMAP4K4KCNH2 | |
| SCHEMBL3170198 | 0.80 | EGFR (0.34) | EGFRMAP4K4KCNH2MEN1KMT2A | |
| SCHEMBL3333259 | 0.78 | CYP2A6 (0.43) | EGFRMAP4K4KCNH2 | |
| SCHEMBL23084868 | 0.76 | KCNH2 (0.44) | EGFRMAP4K4KCNH2PDE2AMEN1 | |
| SCHEMBL18544271 | 0.76 | EGFR (0.39) | EGFRMAP4K4KCNH2MEN1KMT2A | |
| SCHEMBL1723539 | 0.76 | PDE10A (0.39) | EGFRMAP4K4KCNH2PDE2AMEN1 | |
| SCHEMBL3333253 | 0.76 | NNMT (0.38) | MAP4K4KCNH2MEN1KMT2A | |
| SCHEMBL15979006 | 0.75 | EGFR (0.33) | EGFRMAP4K4KCNH2PDE10A | |
| SCHEMBL590199 | 0.75 | MAP4K4 (0.44) | EGFRMAP4K4KCNH2MEN1KMT2A | |
| SCHEMBL592797 | 0.75 | EGFR (0.44) | EGFRMAP4K4KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560821-B1 | ANTIBACTERIAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1560821-B1 | ANTIBACTERIAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1560821-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7232832-B2 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232832-B2 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232832-B2 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060166977-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1560821-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004096982-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166977-A1 | Antibacterial agents | NQO2, NRDC, IFNG | EGFR 4455/4885MAP4K4 993/4885KCNH2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.